Respiratory Infections News

The FDA halted the use of two monoclonal antibody treatments for COVID-19 because they are not effective against the omicron variant of SARS-CoV-2, which now accounts for almost all U.S. cases.

A study published in JAMA Pediatrics reported high morbidity and mortality rates among hospitalized children and adolescents with COVID-19 in 6 sub-Saharan African countries, even among those who were otherwise healthy.

Text messaging showed promise as a surveillance tool to identify acute respiratory infections over a 5-year period in New York City, researchers found.

The FDA recently announced it has expanded its approval of Gilead Sciences’ antiviral drug remdesivir — marketed in the U.S. as Veklury — to allow certain outpatients with COVID-19 to receive it.

In this episode, Joel M. Gelfand, MD, MSCE, is joined by Leonard H. Calabrese, DO, and Amesh Adalja, MD, FIDSA, as they discuss quarantine and isolation guidelines, emerging therapies to treat COVID-19, and the anticipated future of the COVID-19 pandemic.

Booster doses of COVID-19 vaccine provide the best protection against the omicron variant, according to data from three new studies published Friday, including two in MMWR.

In late November, at the behest of independent advisors, WHO classified omicron as a SARS-CoV-2 “variant of concern” amid signs that it was highly transmissible and carried an increased risk for reinfection.

I completed medical school and internal medicine residency in the years immediately before protease inhibitors against HIV reached the clinic.

Last week, the CDC updated its consumer COVID-19 mask guidance to say for the first time that people can wear N95 or KN95 respirators.

A small study found no evidence that mothers infected with SARS-CoV-2 transmitted the virus to their babies through breast milk, affirming previous studies.